
views
Directa Plus – argues recent “strong performance”, but how strong really?
Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced that it “now expects revenues for FY22 to be not less than €10.8m, as a result of a strong performance in December, which represents a c.25% increase on the prior year” and that there is current “robust growth across all verticals supported by a strengthening pipeline of potential opportunities”. So what of a share price presently up to 86p?- By Steve Moore
- 2023-02-27 14:54:48